Alba Rubio-San-Simón
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Alba Rubio-San-Simón has a total of 387 co-authors. Here are the top co-authors by number of shared publications:
- Adela Cañete
Hospital Universitario y Politècnico La Fe, 46026 Valencia, Spain
20 shared publications - Birgit Geoerger
Department of Pediatric and Adolescent Oncology, Gustave Roussy, Université Paris-Saclay, Villejuif, France
19 shared publications - Aroa Soriano
Childhood Cancer and Blood Disorders Group, Vall d'Hebron Institut de Recerca (VHIR), Universitat Autònoma de Barcelona, Barcelona, Spain
18 shared publications - Gudrun Schleiermacher
Institut Curie, Paris, France
18 shared publications - Michela Casanova
Pediatric Oncology Unit, Fondazione IRCCS Istituto Nazionale Tumori, Milano, Italy
18 shared publications - Guy Makin
Royal Manchester Children's Hospital, Manchester, United Kingdom
17 shared publications
Latest Publications
- 1 August 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Precision Oncology
- Vol. 10 (9)
Establishing a Multicenter Personalized Medicine Program in Childhood, Adolescent, and Young Adult Cancer in Spain: The SEHOP-PENCIL Project
Pediatric cancer care in Spain lacked a national personalized medicine program. The SEHOP-PENCIL initiative, established by the SEHOP, was designed to address this gap. A national survey identified the genomic sequencing needs of hospitals treating pediatric patients with cancer. Results showed improved access to targeted next-generation sequencing panels but revealed persistent variability in implementation, limited availability of advanced sequencing (whole-exome sequencing, whole-genome sequencing, RNA sequencing, and DNA methylation profiling), and gaps in cancer predisposition clinics and molecular tumor boards (MTBs). SEHOP-PENCIL is organized as a network of 10 specialized genomic centers serving 45 hospitals through a centralized inclusion system. The program standardizes patient eligibility, genomic workflows, and result interpretation, supported by a national MTB. This framework enables informed clinical decision making, ensures access to molecular diagnosis and innovative therapies, and supports systematic data collection to advance pediatric cancer research and personalized care. SEHOP-PENCIL represents a pioneering national model for integrating precision oncology into pediatric cancer care in Spain. By fostering collaboration, standardizing genomic practices, and promoting equitable access, it aims to reduce disparities and improve outcomes, offering a scalable example for other decentralized health care systems.
- 1 August 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Precision Oncology
- Vol. 10 (9)
Establishing a Multicenter Personalized Medicine Program in Childhood, Adolescent, and Young Adult Cancer in Spain: The SEHOP-PENCIL Project
Pediatric cancer care in Spain lacked a national personalized medicine program. The SEHOP-PENCIL initiative, established by the SEHOP, was designed to address this gap. A national survey identified the genomic sequencing needs of hospitals treating pediatric patients with cancer. Results showed improved access to targeted next-generation sequencing panels but revealed persistent variability in implementation, limited availability of advanced sequencing (whole-exome sequencing, whole-genome sequencing, RNA sequencing, and DNA methylation profiling), and gaps in cancer predisposition clinics and molecular tumor boards (MTBs). SEHOP-PENCIL is organized as a network of 10 specialized genomic centers serving 45 hospitals through a centralized inclusion system. The program standardizes patient eligibility, genomic workflows, and result interpretation, supported by a national MTB. This framework enables informed clinical decision making, ensures access to molecular diagnosis and innovative therapies, and supports systematic data collection to advance pediatric cancer research and personalized care. SEHOP-PENCIL represents a pioneering national model for integrating precision oncology into pediatric cancer care in Spain. By fostering collaboration, standardizing genomic practices, and promoting equitable access, it aims to reduce disparities and improve outcomes, offering a scalable example for other decentralized health care systems.
- Open Access
- 25 July 2026
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 73 (9) , e70558
Impact of Metastatic Patterns on Survival and Response to Therapy in Neuroblastoma
Background: While the presence of metastases in neuroblastoma (NB) is a well‐established prognostic factor, the clinical significance of dissemination patterns and tumour burden and their impact on response and survival remains poorly understood. Objectives: To characterise metastatic dissemination patterns and tumour burden in NB, evaluate their response to induction therapy, and determine their prognostic impact. Methods: We retrospectively analysed 53 patients with metastatic NB between 2010 and 2024 in a reference tertiary care hospital and treated as per SIOPEN protocol or standard‐of‐care recommendations. Responses were recorded as per INRC 2017. Survival was estimated using Kaplan–Meier analysis, and associations between metastatic patterns and outcomes were evaluated by univariate analysis. Results: The most frequent metastatic sites were bone (77%), regional lymph nodes (64%), and bone marrow (55%). MSI (metastatic site index) was 1 ( n = 13), 2 ( n = 13), 3 ( n = 15), or ≥4 ( n = 12). Overall response according to INRC after induction therapy achieved complete ( n = 1), partial ( n = 41), minor ( n = 6) responses, stable ( n = 4) or progressive disease ( n = 1). Regarding metastatic response, regional and distant lymph nodes, renal and pulmonary decreased in size by 66%, 85%, 90 and 99%, respectively. The median SIOPEN score decreased from 16.5 to 0. Bone marrow infiltration disappeared in 82%. High tumour burden strongly correlated with poor outcomes. Conclusions: Presence of renal metastases, ascites, bone marrow infiltration, high tumour burden at diagnosis and post‐induction pulmonary or renal metastases are negative prognostic markers. Incorporating these factors into risk stratification may guide personalised treatment strategies. Future work should elucidate the genomic background and underlying causes of these different metastatic patterns.
- 25 July 2026
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 73 (9) , e70558
Open AccessImpact of Metastatic Patterns on Survival and Response to Therapy in Neuroblastoma
Background: While the presence of metastases in neuroblastoma (NB) is a well‐established prognostic factor, the clinical significance of dissemination patterns and tumour burden and their impact on response and survival remains poorly understood. Objectives: To characterise metastatic dissemination patterns and tumour burden in NB, evaluate their response to induction therapy, and determine their prognostic impact. Methods: We retrospectively analysed 53 patients with metastatic NB between 2010 and 2024 in a reference tertiary care hospital and treated as per SIOPEN protocol or standard‐of‐care recommendations. Responses were recorded as per INRC 2017. Survival was estimated using Kaplan–Meier analysis, and associations between metastatic patterns and outcomes were evaluated by univariate analysis. Results: The most frequent metastatic sites were bone (77%), regional lymph nodes (64%), and bone marrow (55%). MSI (metastatic site index) was 1 ( n = 13), 2 ( n = 13), 3 ( n = 15), or ≥4 ( n = 12). Overall response according to INRC after induction therapy achieved complete ( n = 1), partial ( n = 41), minor ( n = 6) responses, stable ( n = 4) or progressive disease ( n = 1). Regarding metastatic response, regional and distant lymph nodes, renal and pulmonary decreased in size by 66%, 85%, 90 and 99%, respectively. The median SIOPEN score decreased from 16.5 to 0. Bone marrow infiltration disappeared in 82%. High tumour burden strongly correlated with poor outcomes. Conclusions: Presence of renal metastases, ascites, bone marrow infiltration, high tumour burden at diagnosis and post‐induction pulmonary or renal metastases are negative prognostic markers. Incorporating these factors into risk stratification may guide personalised treatment strategies. Future work should elucidate the genomic background and underlying causes of these different metastatic patterns.
- Open Access
- 1 April 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S4 from Phase I/II Study of the PARP Inhibitor Olaparib and Irinotecan in Children and Young Adults with Recurrent/Refractory Malignancies: Arm D of the AcSé-ESMART Trial
Dose Levels of Arm D and Probabilities of Toxicity at the End of Dose Escalation (n=24 Patients Evaluable for DLT) and after the Whole Study (n=65 Patients Evaluable for DLT)
- 1 April 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S4 from Phase I/II Study of the PARP Inhibitor Olaparib and Irinotecan in Children and Young Adults with Recurrent/Refractory Malignancies: Arm D of the AcSé-ESMART Trial
Dose Levels of Arm D and Probabilities of Toxicity at the End of Dose Escalation (n=24 Patients Evaluable for DLT) and after the Whole Study (n=65 Patients Evaluable for DLT)
- Open Access
- 1 April 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S8 from Phase I/II Study of the PARP Inhibitor Olaparib and Irinotecan in Children and Young Adults with Recurrent/Refractory Malignancies: Arm D of the AcSé-ESMART Trial
Somatic Driver Mutations (A), Focal Amplification/deletions (B) or Gene Fusions (C) and Germline Mutations (D) Detected in 65 Patients Explored in the Molecular Analysis.
- 1 April 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S8 from Phase I/II Study of the PARP Inhibitor Olaparib and Irinotecan in Children and Young Adults with Recurrent/Refractory Malignancies: Arm D of the AcSé-ESMART Trial
Somatic Driver Mutations (A), Focal Amplification/deletions (B) or Gene Fusions (C) and Germline Mutations (D) Detected in 65 Patients Explored in the Molecular Analysis.
- Open Access
- 1 April 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S6 from Phase I/II Study of the PARP Inhibitor Olaparib and Irinotecan in Children and Young Adults with Recurrent/Refractory Malignancies: Arm D of the AcSé-ESMART Trial
Comparison of Homologous Recombination Deficiency (HRD) Scores and Tumor Mutational Burden (TMB) Between Treatment Responders and Non-Responders.
- 1 April 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S6 from Phase I/II Study of the PARP Inhibitor Olaparib and Irinotecan in Children and Young Adults with Recurrent/Refractory Malignancies: Arm D of the AcSé-ESMART Trial
Comparison of Homologous Recombination Deficiency (HRD) Scores and Tumor Mutational Burden (TMB) Between Treatment Responders and Non-Responders.
- Open Access
- 1 April 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from Phase I/II Study of the PARP Inhibitor Olaparib and Irinotecan in Children and Young Adults with Recurrent/Refractory Malignancies: Arm D of the AcSé-ESMART Trial
Representativeness of Study Participants
- 1 April 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from Phase I/II Study of the PARP Inhibitor Olaparib and Irinotecan in Children and Young Adults with Recurrent/Refractory Malignancies: Arm D of the AcSé-ESMART Trial
Representativeness of Study Participants
- Open Access
- 1 April 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from Phase I/II Study of the PARP Inhibitor Olaparib and Irinotecan in Children and Young Adults with Recurrent/Refractory Malignancies: Arm D of the AcSé-ESMART Trial
Progression Free Survival (PFS) and Overall Survival (OS) in Patients Treated in Arm D.
- 1 April 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from Phase I/II Study of the PARP Inhibitor Olaparib and Irinotecan in Children and Young Adults with Recurrent/Refractory Malignancies: Arm D of the AcSé-ESMART Trial
Progression Free Survival (PFS) and Overall Survival (OS) in Patients Treated in Arm D.